Wuhan Renfulikang Pharmaceutical

Wuhan Renfulikang Pharmaceutical is a core subsidiary of Humanwell Healthcare, a prominent Chinese pharmaceutical group headquartered in Wuhan. The company focuses on the research, development, and large-scale production of chemical drug preparations, particularly in the fields of anesthesiology and analgesia. Renfulikang operates state-of-the-art manufacturing facilities that adhere to international GMP standards, enabling the production of high-quality generic and innovative small molecule therapeutics. Its portfolio includes a range of injectable and oral medications designed to address critical needs in pain management and central nervous system disorders. As an integral part of the Humanwell ecosystem, the company contributes to the group's global expansion strategy through its robust R&D capabilities and manufacturing excellence. Renfulikang continues to advance its pipeline by focusing on complex formulations and value-added medicines for the domestic and international markets.